Йомерон

Iomeprol

Advertisements

Treatment option: Angiography, Venography, Visceral Arteriography, Computed Tomography Scan, Left Ventriculography, Myelogram, Peripheral Angiography, Urography, Cerebral Arteriography, Digital Subtraction Angiography

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Йомерон

What is Йомерон? (Iomeprol)

Property	Description
Active ingredient	Iomeprol
Form	Sterile solution for injection
Pharmacological class	Iodinated Contrast Medium
General purpose	Diagnostic visualisation (X-ray enhancement)
Origin	Synthetic, non-ionic monomeric compound

Classification and Origin: What Type of Agent is Йомерон?

Йомерон is a specialized diagnostic chemical agent defined by its active ingredient Iomeprol, which belongs to the class of Iodinated Contrast Media. This agent is a dedicated synthetic non-ionic monomeric compound, engineered specifically to contain a high amount of iodine. Iomeprol is utilized for its role in modern diagnostic imaging.

The non-ionic chemical structure of Iomeprol is a key feature, signifying that the molecule does not dissociate into charged particles in solution. This characteristic is often associated with lower osmolality compared to earlier ionic agents. This makes it a preferred radiographic contrast agent intended solely for enhancing imaging clarity.

Composition and Form: Is Йомерон a Tablet or an Injection?

Йомерон is supplied as a sterile solution for injection, ensuring the compound can be administered directly into the circulatory system via the intravascular route (intra-arterially or intravenously). The core composition is the triiodinated non-ionic radiographic contrast agent Iomeprol dissolved in a sterile aqueous vehicle.

As a single active ingredient product, its various available strengths (e.g., Iomeron 300, 350, 400) primarily reflect the specific amount of iodine present per milliliter. These concentrations are used for enhancing computed tomography (CT) imaging.

Primary Purpose: What General Benefit Does Йомерон Provide?

The primary purpose of Йомерон is to function as a temporary marker that facilitates high-quality radiological visualisation within the body, serving solely as a diagnostic aid. The heavy element iodine within the Iomeprol structure causes robust X-ray attenuation—the physical blocking of X-rays—which is essential for creating an image.

When the solution is introduced, this mechanism results in the clear opacification and delineation of internal structures, such as blood vessels or organ tracts. A typical use scenario involves its application for detailed diagnosis of vascular issues, where the enhancement of image detail allows medical professionals to obtain accurate anatomical information.

Advertisements

What side effects are possible with Йомерон?

Possible side effects and safety information

Adverse Reaction Scope

Classification Scope	Official Regulatory Description
Frequency (Common)	Headache, Nausea, Vomiting, and a transient feeling of warmth or flushing.
System-Organ Classes	Adverse reactions are classified across body systems including Gastrointestinal, Nervous System, Immune System, Vascular, and Renal and Urinary Disorders.
Serious Reactions	Officially documented severe events include Anaphylactoid Shock, Cardiac Arrest, Acute Kidney Injury (Contrast-Induced Nephropathy), Convulsions, and Severe Cutaneous Adverse Reactions (e.g., SJS/TEN).

Safety Restrictions and Considerations

The regulatory safety profile highlights risks for specific patient groups and limitations on use. The agent is Contraindicated in patients with a known hypersensitivity to Iomeprol. Inadvertent intrathecal administration is strictly prohibited as it is associated with severe, potentially fatal outcomes.

Safety requires special consideration for patients with pre-existing Renal Impairment due to an increased risk of Acute Kidney Injury. Pediatric patients (ages 0 to 3 years) require monitoring due to a documented risk of thyroid dysfunction following administration. Furthermore, the label notes that the administration can interfere with Radioactive Iodine Thyroid Testing for several weeks.

Adverse reactions may be Immediate (e.g., severe hypersensitivity, typically minutes after injection) or Delayed (e.g., skin reactions, occurring hours to days later), as specified in regulatory documentation.

Regulatory Safety Summary

Common Adverse Reactions are often mild and limited to the Nervous and Gastrointestinal Systems.
Serious Adverse Reactions involve major systems (Cardiovascular, Immune, Renal) and are explicitly documented and classified in governmental labels.
Official documentation includes specific constraints for patients with Renal Impairment and notes regarding Thyroid Function risk.

This official safety information formally structures the understanding of risks by separating mild and transient reactions from potentially life-threatening Serious Adverse Reactions. This regulatory framework categorizes events by both their documented frequency and the specific system-organ classes affected, defining the established safety boundaries within the product label.

Advertisements

Overdose and Emergency Response

Overdosage with Йомерон is officially documented by regulatory authorities as a life-threatening event that affects the pulmonary and cardiovascular systems. Overexposure, which may be caused by an excessive dose or impaired excretion, requires immediate emergency medical attention.

Documented clinical manifestations of overdosage include severe cardiovascular reactions such as hypotension, shock, cardiac arrest, and pulmonary oedema. Neurological manifestations of Contrast Encephalopathy are also officially reported, presenting with symptoms including seizures, confusion, cerebral oedema, and potentially coma.

When to Seek Urgent Help Regulatory instructions mandate that administration must be ceased immediately upon the suspicion of severe reactions, such as severe cutaneous adverse reactions or signs of neurological dysfunction. Patients must be monitored for severe cardiovascular reactions following exposure. Treatment of overdosage is directed toward the support of all vital functions and the prompt institution of symptomatic therapy. Iomeprol is officially documented as dialyzable for procedural removal in cases of systemic overexposure; no specific antidote is known.

Official documentation notes specific risk factors, including increased susceptibility in neonates and young children to haemodynamic alterations, and higher risk of cardiac complications in the elderly.

Therapeutic Uses of Йомерон

What Йомерон Treats: Main Diagnostic Uses and Benefits

Йомерон is considered relevant for high-definition imaging when patients experience symptoms related to physical discomfort or noticeable physiological strain, which may suggest underlying structural or circulatory issues. Its use is relevant in clinical settings that involve acute or unstable symptom patterns, supporting the essential step of assisting with a diagnosis. The agent supports accurate anatomical delineation across several key procedures, including coronary arteriography, aortography, cerebral arteriography, and Computed Tomography (CT) of the head and body.

In these scenarios, the key utility is the enhanced clarity in imaging, which assists with maintaining functional stability by supporting the critical step from symptom presentation to diagnosis. This focus on objective imaging is why its role is often summarized as: “provides support that helps ease the overall symptom burden which may assist with subsequent treatment options.” It is commonly used when symptoms become temporarily overwhelming, providing essential information that may assist with subsequent treatment being appropriately targeted for **conditions presenting with systemic or localized discomfort.

Quick Fact: Clarity for Structural and Circulatory Issues

Quick Fact: Clarity for Structural and Circulatory Issues. The primary use of this agent is to enhance imaging contrast, a supportive step relevant for managing conditions characterized by periods of heightened symptoms by supporting the visibility of the underlying physical cause for medical professionals.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Йомерон (Iomeprol) — Official Regulatory Information

This map presents the official population eligibility and non-eligibility status for the diagnostic agent Iomeprol (Йомерон), based strictly on governmental regulatory documents.

Eligibility Scope

Category	Regulatory Status (Strictly Labeled Information)
Populations for whom use is allowed	Adults and Pediatric Patients are approved for various intra-arterial and intravenous diagnostic procedures.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Iomeprol or a history of Severe Cutaneous Adverse Reaction (SCAR) must not use the medicine. Intrathecal administration is absolutely contraindicated.
Pregnancy and lactation eligibility status	Pregnancy use must be avoided unless there is no safer alternative. Stopping breastfeeding is unnecessary as excretion into breast milk is minimal.

Eligibility-Related Restrictions

Category	Condition-Specific Limitations (Official Labeling Only)
Age-related eligibility rules	Neonates/Infants (under 1 year) are particularly susceptible to electrolyte imbalances. Children 0 to 3 years require thyroid function monitoring post-administration.
Condition-specific eligibility rules	Patients with pre-existing Renal Impairment, Hyperthyroidism, Pheochromocytoma, or Sickle Cell Disease require restricted use with specialized caution and management (e.g., hydration). Angiography is not recommended in patients with Homocystinuria.

Connection to the overall eligibility profile

Official regulatory documents define eligibility by establishing absolute non-eligibility for hypersensitivity or SCAR, prohibiting specific administration routes, and imposing mandatory conditional restrictions for populations with certain pre-existing comorbidities (e.g., renal impairment) or physiological states (e.g., pregnancy). This structure dictates precisely which patient groups are approved for use and which are excluded or require specialized management as a condition of eligibility.

Advertisements

What should I know about interactions with other medicines?

Йомерон (Iomeprol) interactions are governed by effects on renal clearance and diagnostic integrity, as the contrast agent does not undergo significant metabolism; there are no officially documented interactions involving Cytochrome P450 enzymes.

Conditional Pharmacokinetic Restriction and Timing Rules

The regulatory documents establish a critical restriction involving Metformin. Due to the contrast agent’s potential to cause a transient reduction in renal function, co-administration may decrease the renal clearance of Metformin, resulting in increased plasma exposure and an officially documented risk of lactic acidosis. Mandatory timing rules require Metformin cessation prior to administration in patients with specific eGFR ranges or pre-existing conditions, including hepatic impairment and a history of alcoholism or heart failure.

Diagnostic and Pharmacodynamic Interference

The high iodine content of Iomeprol interferes with subsequent diagnostic or therapeutic use of Radioactive Iodine (I-131, I-123). This interference decreases efficacy, necessitating a regulatory-mandated avoidance period of 6 to 8 weeks. Furthermore, the co-administration of drugs that lower the seizure threshold is associated with an additive pharmacodynamic risk of seizures. For these agents, the official labeling requires mandatory discontinuation 48 hours before the examination, with treatment not resumed until 24 hours post-procedure. Other substance classes, such as Beta-blockers and ACE-inhibitors, are noted for an increased risk of adverse cardiovascular or hypertensive reactions.

Advertisements

Mechanism of Action

How Йомерон Works: The Physical Mechanism of Contrast

The action of Йомерон (Iomeprol) is rooted in a physical principle—X-ray attenuation—and does not involve classical pharmacological interactions like receptor binding or enzyme inhibition. The compound’s mechanism is initiated by the three heavy iodine atoms (Z=53) bound to the Iomeprol molecule, which serve as the primary physical target for diagnostic X-ray photons.

This atomic configuration induces high photoelectric absorption of the X-rays, creating localized, intense radiopacity. This radiopacity establishes the required physiological condition for differential contrast in imaging.

Following administration, the non-ionic Iomeprol passively distributes throughout the circulatory system and the extracellular fluid space. This flow-dependent distribution facilitates the transient delineation of blood vessels and highly perfused organs. The entire effect is constrained by anatomical barriers, such as the intact blood-brain barrier (BBB), which restricts the agent primarily to the vasculature, and by the rate of blood flow, which determines the concentration and duration of the mechanism.

Advertisements

Dosage and Administration Information

Йомерон (Iomeprol) is a diagnostic agent used only under professional supervision in specialized settings, such as a hospital or clinic. Its application is governed by precise instructions detailed in prescribing information. The administration of this agent is typically a single-event use confined to the duration of the diagnostic procedure and is not part of a chronic or cyclic treatment schedule.

The product is administered exclusively via the intravascular route, specifically through Intravenous (IV) or Intra-arterial (IA) injection, to facilitate imaging enhancement; use via the intrathecal route is explicitly prohibited. Prior to injection, the sterile solution is often warmed to body temperature (37 C) to meet preparation requirements.

Dosing is highly specific and depends on the procedure, the area being imaged, and the chosen concentration, which is available in various strengths such as 300 or 350 mg Iodine/ mL. Volumes for adult CT procedures can range from 75 mL to 190 mL. Conversely, highly specific procedures like selective arteriography use smaller volumes. For pediatric patients, dosing follows a weight- and age-based calculation in mL/ kg to determine the appropriate volume. In older adults, standard practice involves using the lowest dose necessary for the required visualization. Procedural conditions may require administration at rapid injection rates, and unused portions from multi-dose containers must be discarded within 10 hours of first use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Йомерон

Evidence for Use in CT Imaging of the Head and Body

Research has examined Iomeprol's performance in achieving image clarity during procedures like Computed Tomography (CT) scans of the head and the body. The studies conducted were primarily short-term diagnostic performance trials that often compared Iomeprol against other contrast materials or explored different concentrations of the agent. Researchers focused on technical outcomes, such as measuring the increase in contrast enhancement within specific tissues and assessing the overall quality and clarity of the resulting images.

The findings describe patterns where the administration of Йомерон was associated with observed levels of contrast enhancement in tissues and blood vessels, which supported diagnostic assessment. The research reports that the product was observed to meet criteria for diagnostic adequacy, meaning the images were generally clear enough for medical professionals to use for interpretation.

Evidence for Use in Arterial and Vascular Imaging (Angiography)

Йомерон was studied for its use in arterial and vascular imaging (angiography), which involves detailed visualization of the blood vessels. The evidence comes from Randomized Controlled Trials (RCTs) and similar trials that examined the agent's utility in providing the necessary clarity during these invasive diagnostic procedures. The studies monitored the specific outcome of diagnostic visualization quality, using standardized scoring systems to determine if blood vessels were clearly opacified and defined.

Research Gaps and Limitations

When considering the research for diagnostic contrast agents, the typical focus is on the brief period during and immediately after the procedure. The studies that form the basis of the evidence for Йомерон are characterized by defined, limited follow-up durations.

Consequently, there is limited information available from the research regarding any long-term effects on patient health markers or functional status that extend beyond a few days post-procedure. Data for certain specialized or small subgroups defined by specific, complex comorbidities remain insufficient, and findings for these specific situations may be uncertain or based on smaller sample sizes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Йомерон (FAQ)

Q: What is the difference between a contrast agent and a regular medicine?

Official information states that this product is classified as a diagnostic chemical agent and an iodinated contrast medium. Unlike classic therapeutic medicines that rely on chemical interactions to treat a condition, this agent's effect is based on a physical principle: temporarily blocking X-rays to create a clearer image. Regulatory documents also note that the agent is not significantly metabolized by the body.

Q: Does Йомерон change anything in my body besides making the X-ray clearer?

Yes, in addition to enhancing imaging, the administration of this agent is associated with documented effects and potential risks. These can include common, transient feelings like a headache or warmth. The labeling describes various risks, which can include the possibility of acute kidney injury and cardiovascular events, and temporary thyroid changes noted in neonates and infants.

Q: Is Йомерон used for all types of CT scans?

This agent is officially approved for various diagnostic procedures where enhanced visualization is needed. This includes enhancement in Computed Tomography (CT) of the head and body, and angiography (imaging of arteries). However, its use is strictly restricted to the specific indications listed in the official product label.

Q: Can Йомерон be used to visualize soft tissues like muscles?

The mechanism of action is based on the agent's flow-dependent distribution. Official information indicates that it passively distributes throughout the circulatory system and the surrounding extracellular fluid space. This process primarily facilitates the visualization and clear delineation of blood vessels and highly perfused organs.

Q: How long do the headache and nausea from Йомерон typically last?

According to official documentation, common adverse reactions, such as headache and nausea, are generally described as mild and transient in nature. The official documentation indicates that they are typically self-limiting.

Q: What are the signs of a delayed reaction or allergy to Йомерон?

Delayed adverse reactions may occur hours to days after the injection, and these are often noted to include mild skin reactions like hives (urticaria) or a rash. Official safety information specifies that more severe delayed reactions can also occur. For this reason, patients may be monitored after administration for signs of either an immediate or a delayed reaction.

Q: Can Йомерон cause problems with the thyroid gland?

Yes, this agent may affect the thyroid. There is a documented risk of thyroid dysfunction that requires monitoring in pediatric patients aged 0 to 3 years. Additionally, patients with pre-existing conditions like Hyperthyroidism must be approached with special caution.

Q: What is contrast-induced encephalopathy that is mentioned in the safety information?

Contrast encephalopathy is a type of neurological dysfunction documented in official labeling as a possible serious adverse reaction. It may manifest as symptoms such as a severe headache, confusion, seizures, visual disturbance, or in severe cases, a loss of coordination or even coma.

Q: Is an allergic reaction to Йомерон more likely if I have other allergies?

Official documentation indicates that patients with a known history of allergic disorders have an increased risk of hypersensitivity reactions to the contrast agent. These allergic disorders include conditions such as bronchial asthma, food allergies, or drug allergies.

Q: How quickly does Йомерон start working once it is injected?

The agent is designed to distribute passively and flow-dependently throughout the circulatory system and extracellular fluid space after injection. This mechanism begins immediately, resulting in the transient delineation of internal structures necessary for imaging.

Q: How long does Йомерон stay visible in the body on the images?

The imaging effect is transient and directly dependent on the flow and concentration of the agent in the area being examined. It remains visible only for the necessary duration of the diagnostic procedure as it circulates before the process of renal excretion begins.

Q: How long does the body take to get rid of all the Йомерон?

According to official pharmacokinetic data, in patients with normal kidney function, the agent has an elimination half-life of approximately 109 minutes (about 1.8 hours). It is predominantly cleared by the kidneys and is generally excreted almost completely from the body within 24 hours of administration.

Q: Is it possible for the injection site to be sore or swollen after receiving Йомерон?

Yes, official safety information notes that local injection site reactions can occur, including temporary pain, discomfort, or warmth at the injection site. Cases of extravasation (leakage into surrounding tissues) have also been reported, which may cause localized pain and swelling.

Q: Is there a common half-life for Йомерон in the body?

Yes, the reported elimination half-life for this agent in patients with normal kidney function is approximately 109 minutes (about 1.8 hours). This figure refers to the time it takes for the concentration of the agent in the plasma to be reduced by half.

Q: Why do they need to watch me for a period of time after the injection of Йомерон?

Monitoring is a standard procedural step because adverse reactions to contrast agents can be either Immediate or Delayed. Immediate reactions, such as severe hypersensitivity events, typically occur within minutes of injection, while delayed reactions, like some skin rashes, may appear hours to days later.

Q: Why are there different concentrations of Йомерон (e.g., 300 vs 350)?

The agent is available in various concentrations because the choice of strength is highly specific to the diagnostic procedure being performed. The concentration used depends on the area being imaged, and the dosing volume required to achieve adequate image clarity for a medical professional's interpretation.

Q: Is Йомерон safe for people who have a history of asthma or breathing problems?

Patients with a history of bronchial asthma have a documented increased risk of experiencing hypersensitivity reactions after administration. Official regulatory guidance specifies that special caution and medical management is advised for these individuals.

Q: Who is responsible for determining if Йомерон is appropriate for me?

Regulatory documents indicate that the diagnostic agent is administered only under professional supervision. The supervising physician or medical team is generally responsible for evaluating individual medical history and weighing the documented risks and benefits before administration.

Q: Is it true that I may need to be well hydrated before receiving Йомерон?

Hydration before and after administration is often a supportive measure mentioned in clinical practice to reduce the risk of contrast-induced kidney issues, especially in patients who have pre-existing risk factors.

Q: Does Йомерон interfere with the results of a thyroid function test?

Official safety information confirms that the use of this product may interfere with the results of tests for thyroid function. This effect is due to the agent's high iodine content. This interference is in addition to the documented impact on Radioactive Iodine Thyroid Testing.

Q: Is the low osmolality of Йомерон important for patient tolerance?

Yes, this agent is a non-ionic contrast medium. This chemical characteristic is associated with a naturally low osmolality, which is documented as resulting in better patient tolerance compared to contrast agents with high osmolality.

Q: Why might a doctor choose Йомерон over an ionic contrast agent?

Official sources note that this agent is a non-ionic compound. This type of compound is often associated with a lower incidence of adverse reactions and better patient tolerance than older ionic contrast media.

Q: What does it mean that Йомерон is dialyzable?

Official pharmacokinetic data indicates that because the agent is not metabolized and is predominantly excreted unchanged by the kidneys, it can be removed from the body via a medical procedure such as dialysis.

Q: What does the maximum total dose of Йомерон refer to?

The maximum total dose refers to the highest volume or weight of iodine that should be administered to a patient in a single session or procedure. This limit is determined by the specific diagnostic procedure and the concentration of the agent being used.

Q: Can a patient drive or operate machinery immediately after receiving Йомерон?

The official product labeling states that there is no known effect on the ability to drive or operate machines. It is always prudent to check with the administering facility regarding post-procedure instructions, especially if you have experienced side effects.

Q: What are the common ingredients in Йомерон besides the active substance?

Besides the active ingredient Iomeprol, the product is supplied as a sterile solution containing an aqueous vehicle and a small, defined list of excipients, or inactive ingredients. These commonly include water and buffering agents to ensure the solution's stability and compatibility for injection.

Q: Is Йомерон generally appropriate for elderly patients?

Yes, the agent is approved for use in older adults. However, the official instructions specify that the medical team should use the lowest dose necessary to achieve the required visualization when administering the agent to older adults.

Q: Can people with diabetes safely receive Йомерон?

The use of the agent in patients with diabetes is conditional and requires caution. Official labeling identifies patients with diabetes mellitus as having a risk factor for Acute Kidney Injury. Patients taking the drug Metformin must follow mandatory timing rules regarding drug cessation before and after administration.

Advertisements

How should Йомерон be stored and disposed of?

How to Store and Dispose of Йомерон (Iomeprol)

Йомерон must be stored and handled according to specific conditions defined in official regulatory labeling to ensure product integrity.

Required Storage Conditions

Requirement	Specific Condition
Temperature	Store below 30 C
Protection	Must be protected from light

Stability and Handling

When unopened, the product has a shelf-life of five years. The solution must be visually checked for discoloration or particulates before use. For the 500 mL multi-dose container, any unused product must be discarded after 10 hours of the stopper being pierced. The stopper should be pierced only once.